Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.66 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19372016 | 0.83 | UBE2T (0.70) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL226465 | 0.83 | UBE2T (0.70) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL371155 | 0.82 | UBE2T (0.63) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL14834856 | 0.81 | SMN1; SMN2 (0.62) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| Bromide SCHEMBL7601035 | 0.81 | UBE2T (0.68) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL244156 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL244157 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL322456 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL16397518 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| Fluoride SCHEMBL7600822 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340547-A1 | NOVEL COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN THE BRAIN | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2025-11-06 | — | — | US | disclosed |
| EP-3976027-B1 | QUINOLINE DERIVATIVES AS FACTOR XI ACTIVATION INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-05-22 | — | — | US | disclosed |
| US-12304899-B2 | Factor XI activation inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250115620-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12195454-B2 | Compounds for imaging tau proteins that accumulate in the brain | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2025-01-14 | — | — | US | disclosed |
| CN-119019364-A | Uracil derivative and preparation method and application thereof | 石河子大学 | 2024-11-26 | — | — | CN | disclosed |
| EP-4438123-A2 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-0222576-B1 | HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS | PFIZER INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| US-4939140-A | ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1990-07-03 | — | — | US | disclosed |
| WO-1989006651-A1 | 1H-INDAZOLE-3-ACETIC ACIDS AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1989-07-27 | — | — | WO | disclosed |
| EP-0325375-A1 | 1H-indazole-3-acetic acids as aldose reductase inhibitors | PFIZER INC. (US) | 1989-07-26 | — | — | EP | disclosed |
| EP-0322153-A2 | Heterocyclic oxophtalazinyl acetic acids | PFIZER INC. (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0313202-A2 | Process for preparing halomethyl thiazoles | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
| US-3988229-A | Stabilized photopolymerizable polymeric compositions containing a photoinitiator and a nitrone derivative | EASTMAN KODAK COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
| US-3962056-A | MOLDING, COATING | EASTMAN KODAK COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3962055-A | MOLDING, COATING | EASTMAN KODAK COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | UBE2T 2278/4885ASIC3 3317/4885SMN1; SMN2 1667/4885 |
| US-12304899-B2 | Factor XI activation inhibitors | F11, TFPI, F13B | UBE2T 3192/4885ASIC3 2668/4885SMN1; SMN2 4485/4885 |
| US-12195454-B2 | Compounds for imaging tau proteins that accumulate in the brain | MAPT, FABP7, HTT | UBE2T 1751/4885ASIC3 2086/4885SMN1; SMN2 2839/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | UBE2T 3473/4885ASIC3 1046/4885SMN1; SMN2 3679/4885 |
| US-20250115620-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DHFR | UBE2T 3602/4885ASIC3 4712/4885SMN1; SMN2 2994/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | UBE2T 1902/4885ASIC3 2159/4885SMN1; SMN2 1208/4885 |
| US-20250340547-A1 | NOVEL COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN THE BRAIN | MAPT, FABP7, HTT | UBE2T 2027/4885ASIC3 2064/4885SMN1; SMN2 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.